In this free webinar, gain an overview of interstitial lung disease (ILD), including its key characteristics. Attendees will learn about endpoint selection considerations for ILD trials, including objective assessments of disease activity. The featured speakers will share insights into novel technologies that can more accurately monitor cough in ILD clinical trials. The speakers will also discuss trial design strategies to minimize participant burden and maximize enrollment in ILD studies. Attendees will learn about optimized medical imaging solutions and opportunities for decentralization.
TORONTO, April 1, 2025 /PRNewswire-PRWeb/ -- Interstitial lung disease (ILD) represents a diverse group of disorders characterized by infiltration of lung parenchyma with extracellular matrix, leading to progressive respiratory impairment and respiratory failure over time.
Patients often experience debilitating symptoms such as breathlessness and chronic cough, significantly affecting their quality of life and limiting daily activities. Treatment options for ILD are limited and vary based on disease etiology and progression. While antifibrotic agents such as nintedanib and pirfenidone have shown efficacy in slowing disease progression, there remains a significant unmet need with novel therapies directed at both underlying pathophysiology and symptomatic relief under active clinical development.
The application of meaningful and measurable endpoints is essential for the success of ILD clinical trials. However, regulatory challenges persist, particularly in validating novel digital biomarkers and patient-reported outcomes (PROs). Regulatory agencies emphasize the need for standardized, reproducible measures that demonstrate clinical relevance, necessitating rigorous validation studies and alignment with evolving guidelines for digital health technologies (DHTs) in clinical trials.
Register for this webinar to learn about the latest advancements in ILD clinical trial design from endpoint selection and novel cough monitoring tech to patient-centric trial design and imaging solutions.
Join Dr. Todd Lustine, MD, MS, FCCP, Vice President, Medical Science, Respiratory, Clario; Kevin McCarthy, RPFT, Director, Scientific Affairs, Clario; Amit Vasanji, PhD, Vice President, Medical & Scientific Affairs, Clario; and Dr. Peter Cho, PhD, MRCP, FHEA, Adjunct Senior Lecturer, Kings College Hospital NHSFT, for the live webinar on Tuesday, April 22, 2025, at 11am EDT (5pm CEST/EU-Central).
For more information or to register for this event, visit From Symptoms to Solutions: Enhancing Interstitial Lung Disease (ILD) Trials with Next-Gen Assessments.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article